Mona Ashiya - Jan 26, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Signature
/s/ Sukhi Jagpal as attorney-in-fact for Mona Ashiya
Stock symbol
SRRA
Transactions as of
Jan 26, 2022
Transactions value $
$6,434,340
Form type
4
Date filed
1/28/2022, 08:23 PM
Previous filing
Jun 9, 2021
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Exercise of in-the-money or at-the-money derivative security $4.95M +375K +33% $13.20 1.51M Jan 26, 2022 See footnotes (4), F1
transaction SRRA Common Stock Exercise of in-the-money or at-the-money derivative security $742K +56.2K +33% $13.20 227K Jan 26, 2022 See footnotes (4), F2
transaction SRRA Common Stock Exercise of in-the-money or at-the-money derivative security $742K +56.2K +33% $13.20 227K Jan 26, 2022 See footnotes F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Series B Warrants Exercise of in-the-money or at-the-money derivative security $0 -375K -100% $0.00* 0 Jan 26, 2022 Common Stock 375K $13.20 See footnotes F1, F4, F5, F6
transaction SRRA Series B Warrants Exercise of in-the-money or at-the-money derivative security $0 -56.2K -100% $0.00* 0 Jan 26, 2022 Common Stock 56.2K $13.20 See footnotes F2, F4, F6, F7
transaction SRRA Series B Warrants Exercise of in-the-money or at-the-money derivative security $0 -56.2K -100% $0.00* 0 Jan 26, 2022 Common Stock 56.2K $13.20 See footnotes F3, F4, F6, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F2 These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
F3 These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM.
F4 Each of the Reporting Person, OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
F5 Consists of Series B warrants previously held by OPI VII.
F6 The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by the Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis.
F7 Consists of Series B warrants previously held by OPM.
F8 Consists of Series B warrants previously held by Genesis.